A new approach to the treatment of dyslipidemia;Naujas požiuris i dislipidemijos gydyma

Medicina

Volumn 44, Issue 5, 2008, Pages 407-413

  Kevelaitiene, Sigita ^a   Šlapikas, Rimvydas ^a  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

Cholesterol absorption inhibitors; Low density lipoprote cholesterol (LDL C); Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AZETIDINE DERIVATIVE; CHOLESTEROL; EZETIMIBE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG COMBINATION; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PYRROLES; RISK FACTORS;

EID: 45549103690     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina44050053     Document Type: Article

References (37)

1. Schaefer EJ. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 2002;75:191-212.
2. Kovaite M, Petrulioniene Ž, Ryliškyte L, Badariene J, Čypiene A, Dženkevičiute V, et al. Arteriju sienelės rodikliu ryšys su širdies ir kraujagysliu ligu rizikos veiksniais bei širdies ir kraujagysliu ligu rizika remiantis SCORE vertinimo sistema. (Relationship of arterial wall parameters to cardiovascular risk factors and cardiovascular risk assessed by SCORE system.) Medicina (Kaunas) 2007;43:529-41.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III)). JAMA 2001;285:2486-97.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
5. Žaliunas R, Braždžionyte J, Šlapikas R. Šiuolaikinis požiūris i dislipidemiju gydyma. Nacionalinės cholesterolio mokymo programos ekspertu grupės rekomendacijos. (Modern approach to lipid management. New guidelines from the national Cholesterol Education Program Expert Panel.) Medicina (Kaunas) 2001;37:831-8.
6. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
8. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.
9. Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008;29:499-508.
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med 2004;350:1495-504.
11. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.
12. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: Randomized controlled trial. JAMA 2004;291:1071-80.
13. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.
14. Ballantyne CM. Changing lipid-lowering guidelines: Whom to treat and how low to go. Eur Heart J Supplements 2005; 7(Suppl A):A12-9.
15. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
16. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 (Suppl 2):S1-113.
17. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152-60.
18. Ballantyne C. Evolving concepts and a new approach for management of hyperlipidemia. Euro Heart J Supplements 2002;4(Suppl J):J1-15.
19. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipidlowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
20. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E - Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-63.
21. Svilaas A, Risberg K, Thoresen M, Ose L. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol 2000;86:1250-3.
22. Goettsch WG, Yin DD, Alernao E, Klungel OH, Stalenhoef RM, Herings RM. Statins are less effective in common daily practice among patients with hypercholesterolemia: The REALITY-PHARMO study. Curr Med Res Opin 2004;20: 1025-33.
23. Rajagopalan S, Vieira JL, Alemao E, Yin D, Moriguchi EH. he impact of lipid-lowering treatment patterns on LDL-C reduction and goal attainment in secondary prevention in Germany. Prev Con 2006;2:15-26.
24. Bourgault C, Davignon J, Fodor G, Gagne C, Gaudet D, Genest J, et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study - observational (CALISPO). Can J Cardiol 2005;21:1187-93.
25. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21: 1389-99.
26. EUROASPIRE Study Group. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18:1569-82.
27. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
28. Kotseva K, Stagmo M, De Bacquer G, Wood D; on behalf of EUROASPIRE II Study Group. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey. Atherosclerosis 2008;197(2):710-7.
29. Kindermann M, Adam O, Werner N, Bohm M. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol 2007;96:767-86.
30. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
31. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004;26:1758-73.
32. Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571-8.
33. Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, et al. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract 2007;61:1469-80.
34. Person T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007;99:1706-13.
35. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: The VYTAL study. Mayo Clin Proc 2006;81:1579-88.
36. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73.
37. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22: 2041-53.